Fennec Pharmaceuticals Inc (NASDAQ:FENC) — Market Cap & Net Worth
Market Cap & Net Worth: Fennec Pharmaceuticals Inc (FENC)
Fennec Pharmaceuticals Inc (NASDAQ:FENC) has a market capitalization of $311.94 Million ($311.94 Million) as of June 23, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14716 globally and #3434 in its home market, demonstrating a 7.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fennec Pharmaceuticals Inc's stock price $9.53 by its total outstanding shares 34737030 (34.74 Million). Review how much debt does Fennec Pharmaceuticals Inc carry to assess the company's total debt and financial obligations.
Fennec Pharmaceuticals Inc Market Cap History: 2015 to 2026
Fennec Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $60.59 Million to $331.04 Million (17.27% CAGR).
Index Memberships
Fennec Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #396 of 976 |
|
NASDAQ Composite
IXIC
|
$40.53 Trillion | 0.00% | #1429 of 3165 |
Weight: Fennec Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Fennec Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fennec Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.99x
Fennec Pharmaceuticals Inc's market cap is 5.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $258.79 Million | $170.00K | -$18.11 Million | 1522.30x | N/A |
| 2021 | $152.84 Million | $170.00K | -$17.35 Million | 899.08x | N/A |
| 2022 | $333.48 Million | $1.53 Million | -$23.71 Million | 217.25x | N/A |
| 2023 | $389.75 Million | $21.25 Million | -$16.05 Million | 18.34x | N/A |
| 2024 | $219.54 Million | $47.54 Million | -$436.00K | 4.62x | N/A |
| 2025 | $267.48 Million | $44.64 Million | -$9.74 Million | 5.99x | N/A |
Competitor Companies of FENC by Market Capitalization
Companies near Fennec Pharmaceuticals Inc in the global market cap rankings as of June 23, 2026.
Key companies related to Fennec Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $63.10 Billion USD.
- UCB SA (BR:UCB): Ranked #546 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $466.79 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.10 Billion | $612.50 |
| #546 | UCB SA | BR:UCB | $49.68 Billion | €247.60 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €796.00 |
Fennec Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Fennec Pharmaceuticals Inc's market cap moved from $60.59 Million to $ 331.04 Million, with a yearly change of 17.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $331.04 Million | +23.77% |
| 2025 | $267.48 Million | +21.84% |
| 2024 | $219.54 Million | -43.67% |
| 2023 | $389.75 Million | +16.88% |
| 2022 | $333.48 Million | +118.18% |
| 2021 | $152.84 Million | -40.94% |
| 2020 | $258.79 Million | +14.79% |
| 2019 | $225.44 Million | +1.72% |
| 2018 | $221.62 Million | -36.33% |
| 2017 | $348.07 Million | +368.55% |
| 2016 | $74.29 Million | +22.61% |
| 2015 | $60.59 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 23rd, 2026 the market cap of Fennec Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $311.94 Million USD |
| MoneyControl | $311.94 Million USD |
| MarketWatch | $311.94 Million USD |
| marketcap.company | $311.94 Million USD |
| Reuters | $311.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has co… Read more